Eli Lilly and Company

Philip Parker Waid

Sajan Joseph

Michael Robert Wiley

Gerald Floyd Smith

John Joseph Masters

David Kent Herron

Ying Kwong Yee

David Mendel

Angela Lynn Marquart

James E Ray

Jianping Huang

Rima Salim Al-Awar

Kyle Andrew Hecker

Chuan Shih

Guoxin Zhu

Anne Louise Tebbe

Michael Paal

Tiechao Li

Radhakrishnan Rathnachalam

Xun Zhou

This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor. 

Substituted heterocyclic carboxamides with antithrombotic activity

This application relates to a compound of formula I (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.

Substituted carboxamides

This application relates to a compound of formula (I) (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.

Substituted heterocyclic amides

The present invention provides selective kinase inhibitors of formula (I)

Agents and methods for the treatment of proliferative diseases

The present invention provides selective kinase inhibitors of formula (I).

Growing community of inventors

Indianapolis, IN, United States of America

Philip Parker Waid